1. Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder
International Clinical Psychopharmacology, 10/23/09Dougherty DD et al. – The results suggest that the 30 mg (vs. 20 mg) dose of escitalopram may provide a superior reduction in OCD symptoms for those sufferers with comorbid depression and/or anxiety

3. Murphy M et al. – Depressive symptoms emerged as associated with immediate recall, even though few of the participants met the cut–off for caseness. This may indicate a need for intervention in cases of subclinical depression with associated memory complaints. The association between education level and both delayed recall and savings provides support for the cognitive reserve hypothesis, and may suggest useful non–pharmacological approaches to memory deficits in later life.  
4. mproving Clinical Outcomes in Treating Heroin Dependence: Randomized, Controlled Trial of Oral or Implant Naltrexone
Archives of General Psychiatry, 10/09/09
Hulse GK et al. – The naltrexone implant effectively reduced relapse to regular heroin use compared with oral naltrexone and was not associated with major adverse events
Schizophrenia and the incidence of cardiovascular morbidity: A population–based longitudinal study in Ontario, Canada
Schizophrenia Research

No comments:

HOME (*Revenire-Pagina la Zi)